Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 September 2020 | Story Andre Damons | Photo Francois van Vuuren (iFlair Photography)
Dr Lehlohonolo Makhakhe is from the Department of Dermatology at the University of the Free State (UFS).

A senior lecturer and specialist in the Department of Dermatology at the University of the Free State (UFS) has published the very first comprehensive African atlas on skin diseases commonly seen in the African setting. 
The African Atlas, synopsis and practical guide to clinical dermatology also contains more than 1 000 high-resolution images and is intended for medical and nursing students.

Dr Lehlohonolo Makhakhe, a full-time medical specialist (dermatologist) and the author of the book, says this is the first comprehensive full-colour atlas, with contributions from endocrinologists, haematologists, rheumatologists, psychiatrists and the UFS departments of Pharmacology, Dietetics and Paediatrics.

The project started in 2016, after Dr Makhakhe received formal approval from the UFS Ethics Committee and the provincial Department of Health and it was officially published in July 2020 by African Brilliant Minds Publishers. 

The book will have numerous benefits

Dr Makhakhe was a general practitioner with his own practice before joining the UFS to specialise. He then realised that a comprehensive manual was needed, focusing on common skin conditions in our South African setting. He further realised we lacked such a book which would be very beneficial to doctors and nurses. 

“I decided to write this book to encourage unity among doctors in different fields within medicine, particularly at the UFS, and to help promote the culture of writing and producing quality, well-researched, locally brewed content that is relevant to our setting. 
“I also wanted to play a part in providing de-commodified (affordable) books, in the hope of dispensing knowledge and promoting learning for our medical and nursing students to get sound book knowledge, so that they can better manage skin-related pathology,” added Dr Makhakhe.

He said he also aims to create revenue for the university and advance research projects through this book. It also provides an overview of the management of the conditions included in this user-friendly manual.

Challenges during the compilation of the book 

Dr Makhakhe highlighted the huge costs for the publisher, time management of the different contributors, as well as gaining the trust of the contributors for a concept that has never been done before. He aimed to change perceptions relating to dermatology as a secluded and isolated discipline, but also for the department to be seen as an integral part of the medical discipline. 

According to the author of four books (including this one), the publisher is also in talks with many nursing schools across the country to make the book available to nursing students. 

Dr Makhakhe says this atlas was by far his biggest project to date, as his first three books were short stories. He is currently working on a national project with contributors including Prof Johann Schneider (Head: Anatomical Pathology, Stellenbosch University), Prof Jacqueline Goedhals (Head: Anatomical Pathology, UFS), Prof Nndweleni Bida (Head: Anatomical Pathology, University of Pretoria), Prof Faffa Jordaan (Former head of Dermatology, Stellenbosch University) and Prof Wayne Grayson (renowned pathologist in the private sector), which will also be the first of its kind. 
“In summary, the publications are aimed at building a good name for our university through locally produced, high-quality books that are affordable. Once production costs to the publisher are settled, a sizable portion of future proceeds will then be directed to the university as per endorsement protocols.” he stated further.

Dr Makhakhe thanked the Head of the Free State Department of Health, Dr David Motau, the Rector and Vice-Chancellor of the UFS, Prof Francis Petersen, the acting Deputy Director-General of Clinical Services, Dr Marcus Molokomme, and also extended a special word of appreciation to the Head of the School of Clinical Medicine at the UFS, Prof Nathaniel Mofolo, for his assistance and support in making this project a success. He concluded by thanking all the contributors for making time for this historic project. 

The book is now fully endorsed by the UFS and will be offered as part of the curriculum for third- to final-year medical students. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept